Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-01-11, Stock:NVS, The news for the past five days is as follows:
2019-01-04: NEWS1: Tilray Gains More Than 200%: Is There More Scope for Growth?.NEWS2: These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy.
2019-01-07: NEWS1: Cramer Remix: This chipmaker could have another bad quarter—but it&apos;s worth buying now.NEWS2: Cramer Remix: This chipmaker could have another bad quarter—but it's worth buying now.NEWS3: Novartis CEO on chasing cures over profitable treatments.NEWS4: Novartis CEO talks chasing cures over profitable treatments, says they will &apos;ultimately&apos; be valued.NEWS5: Novartis CEO talks chasing cures over profitable treatments, says they will 'ultimately' be valued.NEWS6: Sandoz And Pear Announce US Launch Of ReSET-O To Treat Opioid Use Disorder.NEWS7: Sandoz And Pear Announce US Launch Of ReSET-O To Treat Opioid Use Disorder.
2019-01-08: NEWS1: Novartis Stock Is Poised to Rise Another 15% From Here.NEWS2: Health Care Sector Update for 01/08/2019: AXSM, AKRX, NVS, JNJ, PFE, MRK, ABT, AMGN.NEWS3: Health Care Sector Update for 01/08/2019: AXSM, AKRX, NVS, JNJ, PFE, MRK, ABT, AMGN.NEWS4: The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase.NEWS5: Novartis : FDA Grants Crizanlizumab Breakthrough Therapy Designation.NEWS6: Novartis : FDA Grants Crizanlizumab Breakthrough Therapy Designation.
2019-01-09: NEWS1: Canopy Growth Moves to Key Resistance.NEWS2: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.NEWS3: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.NEWS4: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.
2019-01-10: NEWS1: European ADRs Move Higher in Thursday Trading.NEWS2: European ADRs Move Higher in Thursday Trading.NEWS3: Implied FVD Analyst Target Price: $34.NEWS4: Implied FVD Analyst Target Price: $34.NEWS5: Novartis migraine drug not cost effective - U.K. price watchdog.

Answer: Decrease